Mylocar 60mg Injection: High-Efficiency Targeted Proteasome Inhibitor for Relapsed & Refractory Multiple Myeloma Extensive Product Profile: In-Depth Insights on Mylocar 60mg Injections Mylocar 60mg Injection, manufactured under advanced oncology quality compliance systems within India, is a highly potent targeted antineoplastic formulation. Each single-dose vial contains Carfilzomib ($60text{ mg}$) as a sterile, lyophilized powder intended exclusively for intravenous reconstitution and infusion. Carfilzomib represents a groundbreaking milestone in oncology—it is a second-generation, irreversible tetrapeptide epoxyketone proteasome inhibitor designed to display enhanced structural precision and selective action compared to first-generation options (like bortezomib). 1. Clinical Indications & Target Therapeutic Applications Relapsed or Refractory Multiple Myeloma (RRMM): Indicated for adult patients with multiple myeloma whose disease has returned or grown resistant following one or more previous lines of systemic cancer therapy. Combination Treatment Protocols: To maximize clinical response rates and significantly prolong progression-free survival, Mylocar 60mg is frequently combined with secondary therapeutic agents, including dexamethasone alone, or dexamethasone paired with lenalidomide, daratumumab, or isatuximab. Single-Agent Monotherapy: Approved as a standalone therapeutic regimen for patients whose plasma cell malignancy has progressed after failing both a first-generation proteasome inhibitor and an immunomodulatory agent (IMiD). 2. Comprehensive Mechanism of Action (MOA) Irreversible Binding to the 20S Proteasome: Carfilzomib binds selectively and permanently to the chymotrypsin-like active sites of the 20S proteasome core—the intracellular enzyme complex tasked with degrading damaged or redundant proteins. Toxic Intracellular Protein Accumulation: By putting a dead-stop to proteasome function, Mylocar halts the breakdown of cell cycle regulators and misfolded proteins. This triggers severe, rapid proteotoxic stress within the cell. 3. Storage, Stability, and Handling Protocols Cold-Chain Management: Intact lyophilized vials of Mylocar 60mg must be stored and transported under a verified cold chain strictly maintained between 2°C to 8°C (36°F to 46°F) inside their original outer cardboard box to prevent light degradation. Do not freeze. Reconstitution Guidelines: This medication must be prepared exclusively by a qualified healthcare professional using sterile water for injection. Once reconstituted, it should be administered via a dedicated intravenous line over either 10 or 30 minutes, depending on the specific protocol. Never administer this medication as an intravenous push or bolus. Potential Side Effects of Mylocar 60mg Cardiovascular & Pulmonary Risks: Can cause shortness of breath (dyspnea), pulmonary hypertension (high blood pressure in the lungs), congestive heart failure, myocardial infarction, and sudden blood pressure changes. Full cardiac screening before treatment is highly recommended. Severe Myelosuppression: Significant drops in blood cell counts, causing severe anemia (low red cells leading to extreme fatigue), thrombocytopenia (low platelets increasing bruising or bleeding hazards), and neutropenia (making the body highly vulnerable to infections). Export Documentation & Global Trade Compliance Certificate of Analysis (COA): Providing verifiable batch testing confirming the precise $60text{ mg}$ Carfilzomib strength, absolute sterility profiles, endotoxin limits, and chemical purity indices. Certificate of Origin (COO): Authenticating true manufacturing provenance within registered Indian oncology production lines. Customs-Compliant Manifesting: Precision shipping manifests, clean packing lists, and commercial invoicing marked with correct global harmonized system (HS) codes for seamless clearance. PRESCRIPTION MEDICINE IS YES Disclaimer: This structural product review is prepared strictly for international business-to-business (B2B) trade procurement, wholesale distribution networks, and digital optimization indexing. Mylocar 60mg Injection (Carfilzomib) is a high-potency, restricted prescription oncology medication. It must be prepared and administered exclusively by qualified medical professionals in a hospital or specialized clinical infusion setting. It is unsafe for use during pregnancy or breastfeeding due to severe risks of fetal harm. 📞 Contact Ernest Impex — Pharmaceutical Exporter from India [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD.] 🌐 Websites: www.ernestimpex.com www.ernestvision.com www.oncologymedicinesupplier.com www.ernestpharmaceuticals.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 📲 WhatsApp Link: https://wa.me/919359902383